Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Sherman AC, van Haren SD, Borberg E, Swank Z, Aleissa M, Tong A, Rooks R, Kanwal U, Levine H, Yates B, Izaguirre N, Ryff K, Thomas S, Parisi L, Li X, Walt DR, Levy O, Walsh SR, Issa NC, Baden LR.
Sherman AC, et al. Among authors: issa nc.
Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.05.081. Online ahead of print.
Vaccine. 2024.
PMID: 38862310